
Sign up to save your podcasts
Or
Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about medications for type 2 diabetes.
Listen in as they debate whether metformin should still be first-line for all patients with type 2 diabetes...and discuss the role of GLP-1 agonists and SGLT2 inhibitors in these patients.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
Claim Credit
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
4.8
3636 ratings
Special guest Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute, Lewis and Patricia Dickey Chair in Cardiovascular Medicine, and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University joins us to talk about medications for type 2 diabetes.
Listen in as they debate whether metformin should still be first-line for all patients with type 2 diabetes...and discuss the role of GLP-1 agonists and SGLT2 inhibitors in these patients.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
Claim Credit
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
101 Listeners
501 Listeners
700 Listeners
289 Listeners
257 Listeners
3,334 Listeners
1,143 Listeners
719 Listeners
188 Listeners
513 Listeners
432 Listeners
372 Listeners
138 Listeners
6 Listeners
3 Listeners